BioNTech (BNTX) Q2 FY26 earnings call: guidance and Q&A

What data prompted the decision to choose metastatic CRPC as the first Phase III indication for Elfe-D, and what gives confidence in its competitive differentiation?

Ugur Sahin highlighted the combination of durable disease control and an excellent safety profile for Elfe-D, noting its tolerability and long-term application without significant ILD events, differentiating it from other ADCs. Özlem Türeci added that data presented at ASCO 25 and ESCOGU26 from heavily pretreated populations supported this decision.

“So what is very encouraging for our B7-H3 is the combination of durable disease control plus the so far excellent safety profile that we are seeing for the B7-H3.”

asked by Cory Kasimov · answered by Ugur Sahin

Can you provide an update on expected data readouts for the remainder of the year, specifically regarding China TNBC Phase III data, and whether data will be released via press release or medical meeting?

Özlem Türeci confirmed that the China TNBC Phase III and pumitamig Phase II in CRPC readouts are pushed to 2027 due to event accrual and a desire for more maturity. Key readouts still expected in late 2026 include gotistobart interim analysis for squamous NSCLC, BNT113 interim PFS for head and neck cancer, and TPEM primary analysis for HER2 low breast cancer.

“So with regard to changed milestones and specifically also the China interim analysis test, even for first-line TNBC, we are continuously monitoring events and the data readouts are event driven. And in our China TNBC study, we observed that the events take longer. So the readout is pushed out to 2027 which is in principle is also actually a good sign for us.”

asked by Tazeen Ahmad · answered by Özlem Türeci

Given encouraging Phase II data for pumitamig plus chemo in frontline NSCLC, what preclinical evidence or biomarker features differentiate it as a VEGF PD-1 bispecific?

Ugur Sahin stated that pumitamig's differentiation lies in its improved binding to PD-1 or PD-L1 and its double tumor microenvironment-directed activity. He noted that while direct head-to-head comparisons are not available, the true differentiation will come from the overall portfolio and combinations with ADCs and other compounds.

“We have one feature, which we believe is differentiating with our molecule binding to PD-L1 in the tumor microenvironment. This gives us in principle the opportunity to have a double tumor microenvironment directed compound.”

asked by Xiaochuan Dai · answered by Ugur Sahin

Can you elaborate on the T-Pam comments, specifically the outcome or threshold for HER2 low breast cancer and how various outcomes could impact regulatory and launch strategy?

Özlem Türeci explained that the T-Pam program is broader, including endometrial cancer and breast cancer. For the breast cancer study, benchmarks from other studies in this indication suggest median PFS in the range of 9 to 13 months and 18-month median OS of around 85%. The strategy also involves ongoing signal-seeking studies of T-Pam with pumitamig in different breast cancer patient segments.

“With regard to our breast cancer study, the benchmarks if you compare with published benchmarks, median PFS in the range of 9 to 13 months and 18-month median OS of around 85% according to other studies in this indication and approved treatment.”

asked by Daina Graybosch · answered by Özlem Türeci

With a substantial cash position and pipeline streamlining, what is the 'North Star' for capital deployment and pipeline prioritization?

Helmut Jeggle reiterated unchanged capital allocation priorities: fully funding the priority pipeline, maintaining flexibility for attractive external opportunities, and returning capital via share buybacks. Ugur Sahin added that 2026 focuses on combination trials to identify 'winners' among ADCs and other compounds, which will inform prioritization for Phase III trials in 2027.

“So I would say that our capital allocation priorities remain unchanged. We continue to fully fund our priority pipeline and the commercial capabilities needed to support these upcoming launches.”

asked by Geoffrey Meacham · answered by Helmut Jeggle

What is the company's confidence level for positive interim analyses for the three expected readouts in H2 (HER2, CTLA-4, head and neck cancer vaccine)?

Ugur Sahin stated that while they must await the data, they have positive expectations for each trial. He specifically highlighted gotistobart, noting that if the data from the first part of the Phase III trial are recapitulated, it would be a 'game-changing result' in an indication where docetaxel has been unbeaten for decades.

“You know that if the data for gotistobart that we have seen in the first part of the Phase III clinical trial is recapitulated, this would become a game-changing result in this indication.”

asked by Akash Tewari · answered by Ugur Sahin

Can you quantify how much of the EUR 400 million reduction in revenue guidance midpoint was due to the milestone pushout versus Germany's inventory use and softer COVID demand, and what was the specific partner milestone?

Ramon Zapata stated that approximately 80% of the revenue adjustment is COVID-related, driven by lower demand across markets and the specific impact in Germany from using on-stock vaccine doses. The remaining portion is due to the loss of an out-license milestone, which was not the key driver of the adjustment. He did not specify the partner or program for the pushed-out milestone.

“So I would say, if you would think about percentage, 80% is COVID-related completely and then the rest is the loss of the out-license milestones that we were expecting.”

asked by Jessica Fye · answered by Ramón Zapata-Gomez